Skip to content

Homeopathic treatment of increased uric acid

Effectiveness of Thlaspi bursa pastoris 6C in comparison with Individualized Homeopathic Medicines in Treatment of Hyperuricemia: An Open, Randomized, Pragmatic, Equivalence Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/10/016174
Enrollment
60
Registered
2018-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

Intervention1: Thalapsi bursa pastoris 6C: Thalapsi bursa pastoris 6C in individualized dosage. Each dose shall consist of 4-6 globules (no. 10) of cane sugar, medicated with a single drop of Thalapsi
dosage and repetition depending upon the individual requirement of the cases. The medicine will be procured from a Good Manufacturing Practice (GMP) certified firm. Along with the medicine, lifestyle
dosage and repetition depending upon the individual requirement of the cases. Along with the medicine lifestyle modification (LSM) will be advised in terms of encouraging to have lacto-vegetarian die

Sponsors

National Institute Of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Cases suffering from hyperuricemia since last 3 months 2. Age 18 - 65 years 3. Both sexes 4. Serum uric acid levels above 6 mg/dl (female) or above 7 mg/dl (male). 5. Patients willing to participate in the study and written informed consent of the patients. 6. Literate patients; ability to read English and/or Bengali

Exclusion criteria

Exclusion criteria: 1. Severe or advanced cases requiring surgical procedures or orthopedic corrections of deformities 2. Cases suffering from uncontrolled systemic illness or life-threatening infections or any vital organ failure 3. Cases already undergoing homeopathic treatment for last 3 months for any chronic diseases 4. Patients with psychiatric diseases. 5. Substance abuse and/or dependence. 6. Pregnant women and lactating mothers. 7. Patients not willing to take part in the study

Design outcomes

Primary

MeasureTime frame
Serum uric acid levelTimepoint: At baseline, and after 6 and 12 weeks

Secondary

MeasureTime frame
Gout Assessment Questionnaire measuring gout impact, pain, well being, productivity, and treatment satisfactionTimepoint: At baseline, and after 6 and 12 weeks;Measure Your Medical Outcome Profile (MYMOP 2) questionnaireTimepoint: At baseline, and after 6 and 12 weeks

Countries

India

Contacts

Public ContactUsha Ghelani Uchat

National Institute of Homoeopathy

dr.ushauchatnih2017@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 6, 2026